EICHOR
● Not Yet Recruiting
A Phase II Study of TollB-001 Tablets in Systemic Sclerosis
Condition: Systemic Sclerosis (SSc) · Sponsor: Toll Biotech Co. Ltd. (Beijing)
About this study
The goal of this Phase II study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of TollB-001 Tablets in adults aged 18 to 70 years (male or female) with systemic sclerosis (SSc).
This description comes directly from the study's public registry record.
Talk to the study team
Wang weili · 010-80710966 · wangweili@toll-biotech.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Toll Biotech, 2108-B007, No. 9 West Beisihuan Road, Haidian District, Beijing, People's Republic of China | Beijing, Beijing Municipality, China | — |
| Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07745725